Certified by Founder
Lodge
Kate Therapeutics
start up
United States
- San Diego, California
- 08/06/2023
- Series A
- $51,000,000
Kate Therapeutics (KateTx) is a patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases. The company is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies.
- Industry Biotechnology Research
- Website https://www.katetherapeutics.com/
- LinkedIn https://www.linkedin.com/company/kate-therapeutics/
SkyFi | $12,700,000 | (Jan 15, 2026)
Musical AI | $4,500,000 | (Jan 15, 2026)
Harmattan AI | $200,000,000 | (Jan 15, 2026)
Tive | $20,000,000 | (Jan 15, 2026)
IO River | $20,000,000 | (Jan 15, 2026)
PayMedix | $33,000,000 | (Jan 14, 2026)
bricks.sh | $1,863,303 | (Jan 14, 2026)
Diffraqtion | $4,200,000 | (Jan 14, 2026)
WithCoverage | $42,000,000 | (Jan 14, 2026)
Converge Bio | $25,000,000 | (Jan 14, 2026)